Browsing by Author "Macaya, Carlos (6506673631)"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Cobalt-Chromium KAname™ coRonary stEnt System in the treatment of patients with coronary artery disease (kare study)(2014) ;Carrie, Didier (7006798967) ;Schächinger, Volker (7003997927) ;Danzi, Gian Battista (57209549829) ;Macaya, Carlos (6506673631) ;Zeymer, Uwe (7005045618) ;Putnikovic, Biljana (6602601858) ;Iniguez, Andres (7005329352) ;Moreno, Raul (6506647911) ;Mehmedbegovic, Zlatko (55778381000)Beleslin, Branko (6701355424)Objectives To evaluate the safety and effectiveness of the Kaname™ cobalt-chromium (Co-Cr), thin strut, bare metal stent (BMS) system for the treatment of coronary artery lesions.; Background Despite widespread use of drug-eluting stents, a certain percentage of patients with coronary artery disease are still treated with BMS. Therefore, it is essential to evaluate their clinical performance.; Methods Two hundred eighty-two patients were enrolled in this prospective, single-arm study including a predefined subset of 79 patients with small vessels. The primary end-point was freedom from target vessel failure (TVF) at 6 months. Key angiographic and intravascular ultrasound (IVUS) end-points were late loss, diameter stenosis, binary restenosis, and neointimal hyperplasia volume.; Results Freedom from TVF at 6 months was 93.3% and at 1 year 90.8% in total population, and 92.4% and 87.3% in small vessels, respectively. Clinically driven target lesion revascularization (TLR) rates at 6 and 12 months were 4.3% and 6.4% in total population, and 3.8% and 7.6% in small vessels, respectively. At 6 months in-stent late loss was 0.75 plusmn; 0.43 mm and binary restenosis rate was 16.9% in total population, and 0.64 plusmn; 0.40 mm and 26.1% in small vessels, while IVUS assessed neointimal hyperplasia volume at 6 months was 128.9 plusmn; 42.6 mm3 for total population. There were no definite and probable stent thromboses up to 12 months.; Conclusions Results indicate good safety and effectiveness of the Kaname™ stent with clinically equivalent results in small and larger vessels, as such providing useful treatment option for patients with ischemic heart disease considered for BMS implantation. (J Interven Cardiol 2014;27:491-499) © 2014, Wiley Periodicals, Inc.
